New ETVAX® data will be presented during VASE, a conference designed to spark innovation and accelerate the momentum for research and development on enteric vaccines
Despite the world’s need to focus on COVID-19, diarrheal disease has not gone away. Children are still dying and facing long-term health consequences due to this preventable illness, and new interventions are still urgently needed. The Vaccines Against Shigella and ETEC (VASE) Conference, on September 28 & 30, will provide key updates on vaccines being developed for Shigella, ETEC, and other emerging diarrheal pathogens.
The conference brings together the top minds in the enteric vaccine field; scientists, public health professionals, immunization leaders, vaccine industry representatives, international donors, and other experts around the globe who have the same mission—to share the latest research and ideas toward making enteric vaccines a reality.
While some non-COVID-19 research has had to slow down, we have important research advancements to share. 2 of the 18 presentations at VASE is highlighting our ETEC vaccine candidate ETVAX®. PI Anu Kantele, Helsinki University Hospital, will present data from our completed Phase 2b clinical trial in Benin where the excellent safety and immunogenicity of the ETVAX® was confirmed. Dr. Nsofwa Sukwa, from the Centre for Infectious Disease Research in Zambia, will present results from our recently completed phase 1 age descending study in Zambia where ETVAX ® was shown safe, tolerable, and immunogenic in Zambian adults and children.
This is really a conference for us that care about improving public health and saving lives by reducing diarrheal disease.
